Stay updated on Andexanet Alfa in ICrH with Oral FXa Inhibitor: Clinical Trial
Sign up to get notified when there's something new on the Andexanet Alfa in ICrH with Oral FXa Inhibitor: Clinical Trial page.

Latest updates to the Andexanet Alfa in ICrH with Oral FXa Inhibitor: Clinical Trial page
- Check7 days agoChange DetectedA new revision entry v3.7.0 was added to the record history and the previous revision v3.6.6 was removed. This updates the visible revision trail in the study history without changing substantive content.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedA new release note entry 'Revision: v3.6.6' was added to the history, and the previous 'Revision: v3.6.5' entry was removed, indicating an updated site version.SummaryDifference0.1%

- Check49 days agoChange DetectedThe record history now lists a new revision v3.6.5 and removes v3.6.4 from the timeline, indicating a minor administrative update to the study record. This does not affect the study data or enrolled participants.SummaryDifference0.1%

- Check64 days agoChange DetectedRevision updated on the history page from v3.6.3 to v3.6.4, indicating a recent software release for the site. This update appears in the version history and does not change the study data or visible content.SummaryDifference0.1%

- Check85 days agoChange DetectedRevision tag updated from v3.6.2 to v3.6.3, indicating a new platform/UI version. This update does not modify study data or content on the page, just the version stamp.SummaryDifference0.1%

- Check92 days agoChange DetectedA new revision v3.6.2 was added to the history, and the v3.6.0 entry was removed from the current history view, reflecting an updated record status.SummaryDifference0.1%

Stay in the know with updates to Andexanet Alfa in ICrH with Oral FXa Inhibitor: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Andexanet Alfa in ICrH with Oral FXa Inhibitor: Clinical Trial page.